



Influenza Reagent
Influenza Virus Infectious NYMC BX-115
(B/Zhejiang-Xiacheng/11085/2021) (B-Victoria lineage)
NIBSC code: 23/156
Instructions for use
(Version 1.0, Dated 21/07/2023)

§

1. INTENDED USE

Reagent 23/156 was prepared from NYMC BX-115 (B-Victoria lineage), a reassortant of B/Zhejiang-Xiacheng/11085/2021 (B-Victoria lineage) and NYMC BX-62 (B-Victoria lineage), which was processed in 250µl volumes as liquid stock. The derivation and known passage history of 23/156 are attached.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin.

As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

No unitage is assigned to this material.

4. CONTENTS

Country of origin of biological material: United Kingdom.
Each ampoule contains 250µl (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated chicken eggs.

5. STORAGE

Store in the dark at -70°C or below.

6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL

Ready to use

8. STABILITY

Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

NA

10. ACKNOWLEDGEMENTS

NA

11. FURTHER INFORMATION

Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
<http://www.who.int/biologicals/en/>
JCTLM Higher order reference materials:
<http://www.bipm.org/en/committees/jc/jctlm/>
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
<http://www.nibsc.org/products/ordering.aspx>
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: Clear liquid	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify): Live influenza virus	
Toxicological properties	
Effects of inhalation:	Likelihood of influenza virus infection
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.
Action on Spillage and Method of Disposal	
Spillage of contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biologically hazardous waste.	



15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
Net weight: 0.25g per ampoule
Toxicity Statement: Non-toxic
Veterinary certificate or other statement if applicable.
Attached: No

Passage history of NYMC BX-115 (B-Victoria lineage)

Cumulative number of passages	Passage numbers at each stage	Lot	Laboratory
E3	E2/E1	3000822249	CDC, USA
E13	E2/E1/E10	E#6542	NYMC, USA
E14	E2/E1/E10/E1	47590*	MHRA, UK

* The HA titre of this virus using 0.7% turkey red blood cells is 1024. The infectious titre is unknown.

Sterility: No visible contamination was detected in a variety of media (tryptose soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates) after 14 days incubation.

The HA and NA sequence of this virus are available at GISAID with the accession number EPI_ISL_ 17985119.



Derivation of NYMC BX-115

**B/Zhejiang-Xiacheng/11085/2021 (Victoria lineage) - like High Yield Reassortant (0:1:7)
B/Lee/40: B/Washington/02/2019: B/Zhejiang-Xiacheng/11085/2021
with B/Washington/02/2019 PB2 gene; B/ Zhejiang-Xiacheng/11085/2021 PB1, PA, HA, NP,
NA, M, NS genes**

Exper. # 4894 11/22/2022

B/Zhejiang-Xiacheng/11085/2021 (B/VIC); CDC ID#:3000822249;

Date of collection:11/1/2021; Passage: E2/E1; Date of Harvest:02/10/2022 (Lot #14); HA titer:512


NYMC BX-62 ca: Cold adapted BX-62 (a hybrid strain with B/Washington/02/2019 PB1, PB2, PA, NS and B/Lee/40 HA, NA, NP, M genes)


Passage No.

1 to 3

Passages prior to receipt at NYMC: E3 (E2/E1)

Passage at NYMC





NYMC BX-115 (E1/E2/E9)
E#6542 NYMC archive

HA and NA identified as B/Zhejiang-Xiacheng/11085/2021 by RT-PCR/RFLP analysis of HA and NA genes. RT-PCR/RFLP analysis also identified PB2 gene as B/Washington/02/2019; PB1, PA, NP, M and NS genes (in addition to HA and NA) as B/Zhejiang-Xiacheng/11085/2021.

SPAFAS eggs were used for all passages.

HA titers were performed using chicken red blood cells at room temp.

Virus seeds were shown to be sterile by streaking samples on sheep blood agar plates and incubating for 48 hours at 37 °C.